| Literature DB >> 23659929 |
Carrie B Hurelbrink1, Judith M Spies, Con Yiannikas.
Abstract
Intravenous immunoglobulin (IVIg) is an essential treatment for many neurological, immunological and haematological conditions. However, the severity of its rare adverse effects is often underrecognised. We report a series of 15 patients receiving IVIg for neurological and immunological disorders who developed severe skin reactions. Despite pre-medication, nearly all patients ceased IVIg due to the severity of the adverse response. Interestingly, the majority of patients were male and two-thirds were receiving treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or another inflammatory or demyelinating neuropathy. This marked propensity for male patients with CIDP to develop significant dermatological reactions following IVIg administration has not previously been described. Mechanisms involving the underlying autoimmunity inherent to this condition may play a role.Entities:
Keywords: Adverse effects; Chronic inflammatory demyelinating polyradiculoneuropathy; Intravenous immunoglobulin; Skin reaction
Mesh:
Substances:
Year: 2013 PMID: 23659929 DOI: 10.1016/j.jocn.2012.10.026
Source DB: PubMed Journal: J Clin Neurosci ISSN: 0967-5868 Impact factor: 1.961